Testing effectiveness (Phase 2)Ended earlyNCT01605162
What this trial is testing
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Who this might be right for
Wild Type BRAF Stage IV MelanomaUnresectable Stage III Melanoma
Eisai Inc. 8